CD274 and breast cancer: In the KEYNOTE-355 clinical trial, an improvement in progression-free survival (PFS) was also observed with pembrolizumab plus chemotherapy in untreated patients with locally recurrent inoperable or metastatic triple-negative BC whose tumors expressed PD-L1 with a combined positive score (CPS) ≥ 10 [10].